摘要
目的:分析2021—2023年麻城市某医院降糖药使用情况,为促进临床合理用药提供依据。方法:收集2021—2023年麻城市人民医院降糖药使用情况,包括降糖药物品种、销售金额、用药频度(DDDs)。结果:2021—2023年,麻城市人民医院口服降糖药销售金额呈下降趋势,胰岛素销售金额逐年上升,由于该院引进较多带量采购品种,胰岛素销售金额占比上并无较大增长。2021—2023年,口服降糖药销售金额前三位是α糖苷酶抑制药、双胍类、钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂,(1)α糖苷酶抑制药(共3个品种,阿卡波糖、伏格列波糖、米格列醇),3年平均销售额为861990.47元;(2)双胍类(二甲双胍),3年平均销售额为486325.47元;(3)SGLT-2抑制剂(共2个品种,达格列净、恩格列净),3年平均销售额为275695.81元。2021—2023年口服降糖药DDDs值前三位是格列美脲、二甲双胍、阿卡波糖,其中二甲双胍、阿卡波糖DDDs值逐年上升,格列美脲逐年下降。结论:2021—2023年,胰岛素是麻城市人民医院降糖主流药物,用药金额前3位的是α糖苷酶抑制药、双胍类、SGLT-2抑制剂,DDDs排序前3位是格列美脲、二甲双胍、阿卡波糖,临床用药结构基本合理。
Objective:To analyze the use of hypoglycemic drugs in a hospital in Macheng City from 2021 to 2023,and to provide a basis for promoting rational clinical drug use.Methods:The use of hypoglycemic drugs in Macheng People's Hospital from 2021 to 2023 was collected,including varieties,consumption sum and medication frequency(DDDs)of hypoglycemic drugs.Results:From 2021 to 2023,the consumption sum of oral hypoglycemic drugs in Macheng People's Hospital showed a downward trend,while the consumption sum of insulin increased year by year,due to the introduction of more procurement varieties in the hospital,the proportion of insulin consumption sum did not increase greatly;from 2021 to 2023,the top three sales amounts of oral hypoglycemic drugs are α-glucosidase inhibitors,biguanides,and sodium-glucose cotransporter 2(SGLT-2)inhibitors;①α-glucosidase inhibitors(a total of 3 varieties,acarbose,voglibose,miglitol),the average sales of 3 years was 861990.47 yuan;②biguanide(metformin),the average sales of 3 years was 486325.47 yuan;③SGLT-2 inhibitors(a total of 2 varieties,dapagliflozin,enaglizin),the average sales of 3 years was 275695.81 yuan;the top three oral hypoglycemic drug DDDs values from 2021 to 2023 were glimepiride,metformin and acarbose,among which the DDDs values of metformin and acarbose increased year by year,while glimepiride decreased year by year.Conclusion:From 2021 to 2023,insulin will be the mainstream hypoglycemic drug in the city People's Hospital.The top 3 drugs used are α-glucosidase inhibitors,biguanides and SGLT-2 inhibitors,and the top 3 in the DDDs list are glimepiide,metformin and acarbose.The clinical drug structure is basically reasonable.
作者
熊芸
万兰心
吴谨
卢超
Xiong Yun;Wan Lanxin;Wu Jin;Lu Chao(Department of Pharmacy,Macheng People's Hospital,Macheng 438300,Hubei Province,China)
出处
《中国社区医师》
2024年第16期7-9,共3页
Chinese Community Doctors
关键词
糖尿病
用药频度
降糖药
Diabetes mellitus
Drug use frequency
Hypoglycemic
